New sedative shows promise for ventilated ICU patients
NCT ID NCT06124404
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called remimazolam besylate for sedating patients in the intensive care unit who are on breathing machines. The trial involved 36 adults and compared three different doses to see how well the drug kept patients lightly sedated without needing extra medication. The goal is to find a safe and effective sedation option for this vulnerable group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remimazolam besylate
- What this could lead to
- If successful, this could provide a safer, more controllable sedation option for ICU patients on ventilators.
- What could go wrong
- This is a small, early-phase trial with only 36 participants. The results may not apply to all ICU patients, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MECHANICALLY VENTILATED PATIENTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wuhan Union Hospital
Wuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.